Navigation Links
CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
Date:4/18/2012

SEOUL, South Korea, April 18, 2012 /PRNewswire/ -- CrystalGenomics, Inc., a biopharmaceutical company headquartered in Korea, has just announced positive results from the Phase 2b osteoarthritis (OA) study of the CG100649, CrystalGenomics' next-generation NSAID candidate. The study met its primary and secondary endpoints which were to evaluate the safety, analgesic efficacy and functional benefits of CG100649 (2 mg or 4 mg per day) versus Celebrex® (celecoxib) (200 mg per day) over the 4 week treatment period.

This Phase 2b study was a double-blind, randomized, multicenter, non-inferiority, repeat dose study of CG100649 versus Celebrex in OA patients. Following a 5-14 day washout from all prior pain medications except paracetamol (acetaminophen), subjects recording moderate to severe hip or knee OA pain of 4 to 8 on a 0-10 numerical rating scale were randomized into the study. All subjects received 28 daily doses of either CG100649 2 mg or 4 mg, or Celebrex 200 mg. Anti-arthritic efficacy was evaluated using the standardized WOMAC OA Index and the WOMAC subscales of pain, stiffness, and physical function. The primary efficacy outcome was determined by measuring the change in the average WOMAC-Pain subscale in the index joint at Day 28 vs. Baseline. Secondary efficacy outcomes included the change in the WOMAC Pain at Days 7, 14, 21, 35, and 42; changes in the total WOMAC OA Index at Days 14, 28, and 42, changes in the WOMAC Stiffness & Physical Function subscales at Days 14, 28, and 42; and Subject's Global Assessment and Physician's Global Assessment of OA pain at Days 1, 14, 28 and 42. Throughout the study, both of the CG100649 treatment groups demonstrated non-inferiority compared to Celebrex on all primary and secondary outcome measures.

There were no drug-related serious adverse events (SAEs) in either of the CG100649 treatment groups or in the Celebrex treatment group. Similar non-serious adverse events (AEs) were observed in the CG100
'/>"/>

SOURCE CrystalGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
2. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
3. Pinnacle Biologics Inc. Announces Appointment of Bioprojet Pharma as Exclusive Distributor in Select European Countries
4. Stemline Therapeutics Announces Two Presentations of Direct Injection Synthetic Peptide Vaccine for Brain Cancer, Now Being Developed as SL-701, at the Annual Meeting of the American Association of Cancer Research (AACR)
5. Akorn, Inc. Announces First Quarter 2012 Earnings Release and Conference Call Information
6. Tengion Announces IND Filing for Neo-Kidney Augment Expected During First Half of 2013
7. ConvaTec Healthcare Announces 2011 Year-end Earnings Call
8. The Galien Foundation Announces Prix Galien USA Awards Committee, Chaired by Dr. P. Roy Vagelos
9. Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer
10. Sangamo BioSciences Announces Presentation at the Future Leaders in the Biotech Industry Conference
11. Gamma Pharmaceuticals, Inc. Announces Distribution Agreement for New York Tri-state Area and Purchase Order for Gamma Energy GEL™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Calif. , July 30, 2015  NanoSmart ... drug delivery platforms, has received Orphan Drug Designation ... a second drug product that uses NanoSmart,s proprietary ... formulation of dactinomycin for the treatment of Ewing,s ... The FDA granted NanoSmart,s Orphan Drug Designation on ...
(Date:7/30/2015)... 30, 2015  Cleave Biosciences today announced that ... granted the company a key patent providing the ... CB-5083. This newly issued patent, "Fused ... U.S. 9,062,026, allows for claims on the composition ... oral inhibitor of p97, a critical enzyme that ...
(Date:7/30/2015)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, today announced that ... financial results after the market close on Monday, August ... the same day at 4:30 p.m. ET. ... Officer, and Rick Eiswirth , Chief Operating Officer ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2
... - proves the ability to automatically measure QT ... intervals in even challenging samples, ... NWCI) a cardiac diagnostic and services company, today,revealed the results ... The study was led by an independent industry leading,cardiac safety ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... (NCI), part of the National Institutes of ... clinical trial for patients with,metastatic melanoma using ... the human reovirus. The trial is,being carried ...
Cached Medicine Technology:NewCardio Announces Positive Results From Third Clinical Validation Study 2NewCardio Announces Positive Results From Third Clinical Validation Study 3NewCardio Announces Positive Results From Third Clinical Validation Study 4NewCardio Announces Positive Results From Third Clinical Validation Study 5U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R) 2
(Date:7/30/2015)... ... July 30, 2015 , ... ... Partners All-Star at the annual All-Stars Summit. Google Partners is the platform for ... may receive the full support and tools necessary to run successful search marketing ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... Between ... according to the Health News Florida on June 17th. Those untreated heroin ... exchange programs to prevent the spread of dirty needles throughout the community. Ultimately Florida’s ...
(Date:7/30/2015)... ... 30, 2015 , ... Ocean Hills Recovery has officially been accredited by CARF ... No recommendations means CARF found no areas in the OHR program that needed improvement, ... of all facilities receive. In addition, Ocean Hills was granted the maximum certification period ...
(Date:7/30/2015)... Alexandria, VA (PRWEB) , ... July 30, 2015 ... ... applauds Drug Enforcement Administration (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution ... been scheduled for Saturday, September 26, 2015 from 10:00 AM to 2:00 PM ...
(Date:7/30/2015)... ... 30, 2015 , ... The Tisch Cancer Institute at Icahn ... Tisch Cancer Institute (TCI) at the Icahn School of Medicine at Mount Sinai ... elite group of 69 cancer institutions nationwide that have earned this designation, which ...
Breaking Medicine News(10 mins):Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6
... hundreds of programs helping millions in the,developing world ... April 16 The worldwide,pharmaceutical industry today launched ... companies, global,health leaders and policymakers together to build ... world., Serving as a convening point for ...
... worse disease outcomes and also tend to present to their ... scientists told the 6th European Breast Cancer Conference (EBCC-6) today ... Azambuja and colleagues at the Jules Bordet Institute, Brussels, Belgium, ... showed that women who had a body mass index (BMI) ...
... Nevada Water Authority testifies before Senate,subcommittee, WASHINGTON, ... pharmaceutical compounds in drinking water, scientists must,know at ... simply,whether they can be detected, a leading expert ... behalf of the American Water Works Association (AWWA),Shane ...
... took 2,000 IUs a day lived 26% longer , , TUESDAY, ... high levels of vitamin E seem to live longer than ... comes on the heels of growing concerns regarding the safety ... Alzheimer,s or another illness -- the high dosage in question: ...
... Helps Teenager Attend Classes and Take Trips to the,Mall, ... Rachel Wilhite enjoys hanging out with her friends, shopping,at ... also struggling with a condition that makes her life,very ... that,has serious consequences. When the body cannot process certain ...
... officer also appointed, PLANO, Texas, April 15 ... of LifeCare Holdings, Inc., a,20-facility long term acute care ... B. Douglas has been promoted to president,of the company, ... serve as CFO., McAlister is a seasoned hospital ...
Cached Medicine News:Health News:Worldwide Pharmaceutical Industry Launches Global Health Progress Initiative to Expand Efforts to Improve Health in Developing Countries 2Health News:Worldwide Pharmaceutical Industry Launches Global Health Progress Initiative to Expand Efforts to Improve Health in Developing Countries 3Health News:Obese women disadvantaged in both breast cancer treatment and diagnosis 2Health News:Obese women disadvantaged in both breast cancer treatment and diagnosis 3Health News:AWWA Urges Science-Based Approach in Addressing Pharmaceutical Compounds in Water 2Health News:AWWA Urges Science-Based Approach in Addressing Pharmaceutical Compounds in Water 3Health News:High Doses of Vitamin E Lengthen Lives of Alzheimer's Patients 2Health News:High Doses of Vitamin E Lengthen Lives of Alzheimer's Patients 3Health News:The SCOOTER Store Donates Power Chair to Teenager Struggling With Rare Dwarfism 2Health News:The SCOOTER Store Donates Power Chair to Teenager Struggling With Rare Dwarfism 3Health News:LifeCare Holdings, Inc. Names McAlister Chairman and CEO 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: